Rottapharm Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Monza Italy (1994)
Status: Acquired by Meda Pharmaceuticals (2014) → now Mylan (2016)

Organization Overview

First Clinical Trial
2000
NCT00110474
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Rottapharm Biotech | Rottapharm S.L.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Cardiovascular Diseases (Phase 3)

Constipation (Phase 3)

Dementia (Phase 3)

Fatty Liver (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Hypertriglyceridemia (Phase 3)

Irritable Bowel Syndrome (Phase 3)

Liver Diseases (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Metabolic Syndrome (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Parkinson Disease (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Recurrence (Phase 2)

Syndrome (Phase 3)

Weight Loss (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 20